Synnovation Therapeutics
Yu Bai is a Principal Investigator at Synnovation Therapeutics since May 2022, with prior experience as a Senior Research Investigator and Research Investigator at Incyte from December 2018 to May 2022. Yu served as a Postdoctoral Researcher at Stanford University from October 2016 to November 2018, focusing on the total synthesis of natural products and methodology development. Earlier experience includes roles as a Research Assistant and Teaching Assistant at Purdue University from August 2010 to September 2016, and as a Research Assistant at Nankai University from August 2006 to September 2010. Yu earned a Doctor of Philosophy in Organic Chemistry from Purdue University between 2010 and 2016, having completed an undergraduate program at Nankai University from September 2002 to June 2006.
This person is not in any teams
Synnovation Therapeutics
Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers.It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.